BMS-986353 (Bristol Myers Squibb)

BMS-986353 (formerly CC-98635) is an investigational, autologous tandem chimeric antigen receptor (CAR) T-cell therapy developed by Bristol Myers Squibb for the treatment of relapsed or refractory multiple myeloma. The therapy is engineered to simultaneously target two distinct antigens expressed on the surface of malignant plasma cells: B-cell maturation antigen (BCMA) and G protein-coupled receptor class C group 5 member D (GPRC5D). BCMA is a well-validated target in multiple myeloma, while GPRC5D is a selective myeloma surface antigen with limited expression on non-malignant tissues. By employing a dual-targeting (tandem) approach, BMS-986353 aims to prevent relapse driven by antigen escape—a phenomenon where cancer cells evade treatment by losing or downregulating a single target antigen—thereby potentially increasing the durability and depth of clinical responses compared to single-target CAR T therapies. It is currently in Phase 1 clinical development.

Other names

BCMAxGPRC5D CAR TBCMAxGPRC-5D CAR TBCMAxGPRC 5D CAR TDual Targeting BCMAxGPRC5D CAR Ttandem BCMA/GPRC5D-targeted CAR T-cell therapyBCMA/GPRC5D dual CAR T